Jeff Yass’s MoonLake Immunotherapeutics MLTX Stock Holding History

Jeff Yass’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.82M	Sell	247,742 -93,682	-27%	-$1.7M	﹤0.01%	4683
2026 Q1	$6.36M	Sell	341,424 -207,812	-38%	-$3.44M	﹤0.01%	3838
2025 Q4	$7.24M	Buy	549,236 +354,495	+182%	+$4.18M	﹤0.01%	3485
2025 Q3	$1.4M	Buy	+194,741	New	+$10.1M	﹤0.01%	6561
2024 Q3	–	Sell	-16,964	Closed	-$795K	–	12627
2024 Q2	$746K	Sell	16,964 -55,397	-77%	-$2.35M	﹤0.01%	7265
2024 Q1	$3.63M	Sell	72,361 -141,755	-66%	-$7.69M	﹤0.01%	4162
2023 Q4	$12.9M	Buy	214,116 +196,964	+1,148%	+$10.2M	﹤0.01%	2314
2023 Q3	$978K	Buy	+17,152	New	+$947K	﹤0.01%	6671

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jeff Yass's MLTX Position: Q2 2026 in Review

Jeff Yass reduced its MoonLake Immunotherapeutics (MLTX) stake by 27% in Q2 2026, selling an estimated $1.7M and leaving 247,742 shares worth $4.82M. The position accounts for ﹤0.01% of the portfolio, ranked #4683.

Jeff Yass first reported a position in MLTX in Q3 2023 and has held it in 8 quarters since. The position peaked at $12.9M in Q4 2023. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Jeff Yass held 247,742 shares of MoonLake Immunotherapeutics worth $4.82M as of Q2 2026.
Jeff Yass sold 93,682 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.7M.
MoonLake Immunotherapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4683 holding.
Jeff Yass first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 8 quarters since.
Jeff Yass's MoonLake Immunotherapeutics position peaked at $12.9M in Q4 2023.
172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.